Amgen Continues to Propel BiTE® Technology Innovation | Amgen is a high-quality image in the Cleve collection, available at 3326 × 1482 pixels resolution — ideal for both digital and print use.
Discover how the SCLC bite molecule is revolutionizing small cell lung cancer treatment. This cutting-edge immunotherapy works as a bispecific T-cell engager to target and neutralize tumor cells. Learn about the latest clinical breakthroughs, mechanism of action, and patient outcomes in the fight against aggressive lung malignancies with this innovative targeted therapy approach.
Image Details
| Title | Amgen Continues to Propel BiTE® Technology Innovation | Amgen |
|---|---|
| Dimensions | 3326 × 1482 px |
| Category | Cleve |
| Published | August 5, 2025 |
| Author | Zeus |
| Downloads | 1,143 |
| Views | 640 |
Read full article: Sclc Bite Molecule